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Personalized medicine epitomizes an evolving model of care tailored to the
individual patient. This emerging paradigm harnesses radical technological
advances to define molecular characteristics of each patient and decipher their
unique pathophysiological processes. Translated into individualized algorithms,
the practice of personalized medicine aims to predict, prevent and cure disease
without afflicting therapeutic adverse events. While the transformative power of
personalized medicine is generally recognized by physicians, patients and
payers, the complexity of translating discoveries into new modalities that
transform healthcare is less appreciated. We often consider the flow of
innovation and technology along a continuum of discovery, development,
regulation, and application bridging the bench with the bedside. However, this
process also can be viewed through a complementary prism, as a necessary
supply chain of services and providers, each making essential contributions to
the development of the final product to maximize value to consumers.
Considering personalized medicine in this context of supply chain management
highlights essential points of vulnerability and/or scalability that can ultimately
constrain or potentiate translation of the biological revolution into individualized
diagnostics and therapeutics for optimized value creation and delivery.
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The whole is greater than the sum of the parts ― Aristotle
It is generally appreciated that the revolution in biology is transforming healthcare
from one-size-fits-all therapeutics, to individual tailored disease management.1,2
Science and medicine are increasingly providing molecular solutions that offer
unprecedented opportunities to intervene in disease risk, prevention, prognosis and
cure.3 Emerging technology platforms provide diagnostics that identify corruption of
individual molecular circuits disrupting signaling networks and organismal ecosystems
which can be repaired through genomic, molecular or regenerative interventions
specifically tailored to individual pathophysiology.4 This scientific revolution drives the
development of personalized medicine, which exploits insights in molecular pathology to
generate

tailored

mechanism-based

therapeutics

and

enhance

their

curative

effectiveness, while minimizing adverse events.5 The expanding toolbox of gene-based,
molecular, omic, and regenerative technologies offers unparalleled opportunities to
personalize diagnostics and therapeutics that can be applied across diseases,
ethnicities, and geographies.6, 7
The fruits of this revolution in creating personalized diagnostic and therapeutic
products are generally recognized by patients and their healthcare providers.7,
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What

may be less appreciated is the complexity of processes leading from laboratory-based
discovery to individualized patient management algorithms in practice. We typically
consider the science of translational therapeutics in discreet sequential steps in which
the flow of information and technology moves from left to right along a continuum, from
fundamental discovery of molecular principles and therapeutic targets, to development
involving clinical trials that prove efficacy and safety, through regulatory approval that
certifies the utility of the management approach, to application in patients and
populations – the “DDRU continuum”.3,

9-12

This model broadly categorizes the stages

translating invention into practice. However, it obscures the integral contributions by
individual practitioners and domain-specific experts, and the impact of the external
3

environment, which shape the process at every phase, from discovery to application.
Without considering these individual components, their contributions, and their
relationship to the over-arching continuum, we risk under-estimating points of
vulnerability which can constrain or potentiate the innovation that serves as the lifeblood
of personalized medicine.
It is useful here to borrow a page from the manufacturing sciences to consider
the advanced product development continuum in the context of supply chain
management. In this model, the movement and storage of raw materials, work-inprocess inventories, and finished products from the point of origin to the point of use is
strategically managed to create net value with a competitive infrastructure,
synchronizing supply with demand, and measuring performance globally across the
entire enterprise.13 Indeed, supply chain strategies require a total systems view of the
links in the chain that work together efficiently to create customer satisfaction at the
endpoint of product delivery to the consumer. Efficiencies must be maximized at each of
the component steps to produce added value across the entire continuum to optimize
the benefit to the end user. This concept focuses on total systems efficiency to produce
optimum value by generating the best product while minimizing waste and inefficiency.
In this model, the supply chain is the set of organizations and processes linked by one
or more upstream and downstream flows of products or information from a source to an
end user.
By analogy, the DDRU continuum can be considered a type of product
development/supply chain, with the raw materials of intellectual innovation in
combination with specimens, reagents, and biologicals undergoing transformation by
discovery scientists, clinical trialists, regulatory scientists and clinicians into integrated
diagnostic and therapeutic paradigms that embody personalized medicine for end users
including patients, their healthcare providers, and payers. The essential nature of raw
materials to this supply chain is exemplified by the Commentary by Lu and Flockhart,
4

who propose a national program to collect annotated biospecimens, similar to the
national model for organ donor identification. These authors underscore the critical
vulnerability of the DDRU continuum and innovation in individualized medicine in the
context of limitations in the availability of biospecimens accompanied by full clinical and
demographic annotation. Indeed, in the absence of this essential national resource, the
ability to translate novel genomic observations identified in the laboratory into useful
diagnostic and therapeutic targets that can be applied to disease-specific tailoring of
patient management will undergo progressively greater levels of constraint. These
constraints reflect an inability to validate and confirm clinical utility of the many genomic
associations through standard prospective multicenter blinded clinical trials, which are
logistically and economically infeasible. Rather, retrospective validation of clinical utility
employing annotated biospecimens from a national repository represents an adaptive
solution that creatively aligns resources with needs to maximize value of discoveries to
end users of personalized medicine while minimizing costs and inefficiencies.
Moving along the supply chain, laboratory-based investigations are using those
essential biospecimens in conjunction with emerging technology platforms to create
molecular diagnostic products that are intrinsic components of the personalized
medicine paradigm.12,

14

These diagnostics identify pathophysiological biomolecules

used for disease prediction, risk assessment, prognosis, and diagnosis. Further, these
diagnostics can identify genetic variations in patients creating susceptibility to adverse
therapeutic events. In his Commentary, Kesselheim highlights the recent Supreme
Court decision against the patentability of natural processes.15 For example, developing
a test identifying genetic variants that render patients unable to metabolize a drug,
putting them at risk for toxic adverse events, is ineligible for patentability. Similarly, tests
that define genetic mutations providing prognostic information predicting disease
outcome also cannot be protected by patents. Here, policy decisions external to the
scientific process may negatively shape the supply chain of innovation available to
5

expand personalized medicine. Indeed, the absence of patent protection for these, and
related, discoveries creates an economic vulnerability in the innovation supply chain,
reflecting the absence of a period of market exclusivity for these discoveries
characteristically granted through patent protection. This economic vulnerability
threatens the flow of innovation by constraining investment in the development of
intellectual property that cannot be patent protected. This absence of market exclusivity
could strangle the supply of novel diagnostic products that are essential for downstream
processes translating scientific innovation into the clinical tools supporting the evolution
of personalized medicine.
The negative impact of these policy decisions concerning intellectual property
stands as a striking counterpoint to the innovation in pharmacometabolomics underscored
by Kaddurah-Daouk and her colleagues.16 This State of the Art review highlights the
transformative potential of the study of metabolism at the omic level, to reveal novel molecular
mechanisms underlying inter-individual variability in pathophysiology, drug action, and the
evolution of adverse responses to therapeutics. In turn, these emerging mechanistic insights will
form the basis for novel diagnostic tests based on metabolic signatures of patients that can
specifically target individualized therapeutic approaches, to expand the supply chain of
innovation feeding the personalized medicine paradigm.17-21 Similarly, Momper and Wagner in
their Development remind us of the essential utility of therapeutic drug monitoring as a
cornerstone of classical clinical pharmacology practice which has its origins in the pre-genomic
era.22 This approach continues to provide unique insights into inter-individual variability in
therapeutic responses and adverse events to drugs, especially in cohorts that exhibit highly
dynamic metabolic phenotypes, like the pediatric population. Indeed, co-development of
companion drug monitoring algorithms that accompany novel therapeutic approaches has the
potential to dampen the variability in therapeutic and adverse responses to interventions,
generally, in patient populations, suggesting a position for these approaches in strategies of
supply chain management associated with the development of emerging targeted therapies.22 In
6

that context, it will be important to monitor whether the recent Supreme Court decisions on
intellectual property15 have a negative impact on the advancement of pharmacometabolomics or
companion therapeutic drug monitoring approaches as novel diagnostics driving innovation in
personalized medicine.
Toward the other end of the supply chain, there are emerging challenges in confirming
the utility of novel diagnostic and therapeutic approaches at the center of personalized
medicine. Selker and his colleagues highlight in their State of the Art the potential for standard
clinical development approaches to over-estimate the utility of emerging paradigms in
personalized medicine in general clinical practice. As these emerging approaches embrace
higher orders of molecular specificity and patient individualization, there is a requirement for
standard phase III efficacy trial designs to use highly homogenous populations of patients
carrying the molecular target of interest to reveal clinical efficacy. In that context, efficacy
revealed in these trials may be sufficient to achieve regulatory approval, but may not translate
into true effectiveness in actual clinical practice, where patients are highly heterogeneous with
respect to genotypes and phenotypes, and environments and demographics cannot be closely
defined or controlled. In order to improve the flow of novel technological advancements along
the supply chain from the point of innovation in the laboratory to end users like patients,
healthcare providers and payers, Selker and his colleagues suggest evolving the standard
phase III paradigm into efficacy-effectiveness trials.22 In this model, therapeutic interventions
successfully completing standard phase III efficacy trials in narrowly defined patient populations
would immediately transition into effectiveness trials to estimate the true utility of these
approaches in heterogeneous populations that constitute actual medical practice.

Finally, at the very end of the supply chain, the deluge of omic information, its
relationship to clinical practice, and its utility in maximizing improvements in patient
outcomes while minimizing healthcare costs continues to remain a conundrum to
patients, providers and payers. What are the criteria that support the utility of specific
omic platforms in patient management paradigms? How should patients and providers
7

assess those criteria for their utility, and how should payers assess their ratio of cost to
benefit? It is readily apparent that without solving this conundrum, the supply chain
transforming invention and innovation into end user value will prematurely terminate. In
their State of the Art review, Dotson and colleagues offer one23 of a number24-34 of
algorithms to assess the evidence base supporting implementation of genomic
information into clinical practice and patient management.
Personalized medicine is having a transformative impact on disease risk
assessment, prediction, prevention, prognosis and cure.9,
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The present discussion

highlights the operational flow of technology along a supply chain of innovation, from
laboratory to end users, which requires management at each individual step to
maximize healthcare and economic benefits. Our challenge is to establish the policies
and processes that become an engine driving innovation through this cascade, rather
than a weight dragging down the system.
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